Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?

Migraine is a prevalent disorder and a cause of high disability, influenced by modifiable and non-modifiable risk factors. Comorbid and psychiatric illnesses are prevalent in migraine patients and should be considered when choosing preventive drugs. There have been unforeseen problems with the use o...

Descripción completa

Detalles Bibliográficos
Autor principal: Simioni, Caio Vinicius de Meira Grava
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academia Brasileira de Neurologia - ABNEURO 2022
Materias:
Headache
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491416/
https://www.ncbi.nlm.nih.gov/pubmed/35976315
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491416/
https://www.ncbi.nlm.nih.gov/pubmed/35976315
http://dx.doi.org/10.1590/0004-282X-ANP-2022-S125

Ejemplares similares